Detalhe da pesquisa
1.
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.
Ann Oncol
; 34(9): 734-771, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37343663
2.
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
Ann Oncol
; 33(5): 511-521, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35218887
3.
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Ann Oncol
; 33(1): 67-79, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34562610
4.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Ann Oncol
; 33(2): 181-192, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34839016
5.
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Ann Oncol
; 31(12): 1734-1745, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32976938
6.
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Ann Oncol
; 30(12): 1902-1913, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31566658
7.
Gender medicine and oncology: report and consensus of an ESMO workshop.
Ann Oncol
; 30(12): 1914-1924, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31613312
8.
ESMO Guidance for Reporting Oncology real-World evidence (GROW).
Ann Oncol
; 34(12): 1097-1112, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37848160
9.
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Ann Oncol
; 29(1): 200-208, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29186353
10.
ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Ann Oncol
; 28(10): 2340-2366, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28945867
11.
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Ann Oncol
; 26(8): 1547-73, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26026162
12.
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Ann Oncol
; 30(2): 161-165, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30624547
13.
HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.
Ann Oncol
; 24(11): 2761-6, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23894039
14.
Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'.
Ann Oncol
; 29(3): 774-775, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29161364
15.
Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio.
Ann Oncol
; 29(2): 521-522, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045537
16.
Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al.
Ann Oncol
; 29(5): 1335-1338, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29659680
17.
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).
Ann Oncol
; 24(4): 1011-7, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23136231
18.
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.
ESMO Open
; 8(1): 100604, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36870739
19.
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.
ESMO Open
; 8(3): 101566, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285719
20.
Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio.
Ann Oncol
; 28(8): 2031-2032, 2017 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28430861